Suggested

Trending

Response to Anti–PD-1/PD-L1 Antibody Immunotherapy @CleClinicMD
0:05:57

Response to Anti–PD-1/PD-L1 Antibody Immunotherapy @CleClinicMD
Free
40 Views
10 months ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Cancer Immunotherapy: how to predict results better
00:00:35

Cancer Immunotherapy: how to predict results better
Free
72 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
IMDC Classification Role in Treatment Decision-Making
00:01:07

IMDC Classification Role in Treatment Decision-Making
Free
143 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Clinical Trials on the Use of I-O and TKIs in RCC
00:01:36

Clinical Trials on the Use of I-O and TKIs in RCC
Free
25 Views
1 year ago
Want to watch this again later?
Sign in to add this video to a playlist. Login

Latest Videos

Sigrun Hallmeyer, MD @ACCCBuzz #immunotherapy Immuno-Oncology and What Lies Ahead
0:06:09

Sigrun Hallmeyer, MD @ACCCBuzz #immunotherapy Immuno-Oncology and What Lies Ahead
Free
2 Views
11 hours ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Jacob J. Adashek, DO @MoffittNews @ASCO20 Targetable immune checkpoint molecules may be significantly differentially expressed in minority ethnicities.
0:03:48

Jacob J. Adashek, DO @MoffittNews @ASCO20 Targetable immune checkpoint molecules may be significantly differentially expressed in minority ethnicities.
Free
31 Views
4 days ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Jared Gollob @JaredGollob @KymeraTx #AACR20 What's the Advantage of IRAK4 Combined into One Molecule
0:05:19

Jared Gollob @JaredGollob @KymeraTx #AACR20 What's the Advantage of IRAK4 Combined into One Molecule
Free
3 Views
5 days ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Jared Gollob @JaredGollob @KymeraTx #AACR20 IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor Activity for its Novel STAT3 Degraders
0:05:17

Jared Gollob @JaredGollob @KymeraTx #AACR20 IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor Activity for its Novel STAT3 Degraders
Free
3 Views
5 days ago
Want to watch this again later?
Sign in to add this video to a playlist. Login